Ruxolitinib for treatment of refractory hemophagocytic lymphohistiocytosis

Optimal salvage therapy for refractory HLH is unknown. In our patient, ruxolitinib treatment led to clinical remission of refractory HLH.

Gardado en:
Detalles Bibliográficos
Publicado en:Blood Adv
Main Authors: Broglie, Larisa, Pommert, Lauren, Rao, Sridhar, Thakar, Monica, Phelan, Rachel, Margolis, David, Talano, Julie
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Hematology 2017
Assuntos:
Exceptional Case Report
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5728466/
https://ncbi.nlm.nih.gov/pubmed/29296794
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2017007526
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares